GlassScriptPhysician profile
Bryan G Schwartz
NPI 1861698748
$3,447.93
in general payments reported to CMS, 2019-2025
20 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $13.53 · 2021: $80.02 · 2022: $502 · 2023: $594 · 2024: $965 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,373.44 | 2020-2025 | Impella |
| Inari Medical, INC. | $468.46 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $262.54 | 2019-2025 | Repatha |
| Abbott Laboratories | $260.38 | 2024-2025 | Diamondback Coronary, Navitor, Xience Skypoint |
| Stryker Corporation | $245.18 | 2025 | Artix Mt, Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $214.23 | 2024-2025 | Camzyos, Eliquis |
| Pfizer INC. | $118.31 | 2024-2025 | |
| Teleflex LLC | $117.00 | 2023-2025 | Guideliner, Manta, Turnpike |
| Boston Scientific Corporation | $90.54 | 2023-2025 | Avvigo Guidance System, Mamba |
| Bridgebio Pharma, INC. | $62.33 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.23 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $35.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.58 | 2025 | |
| Irhythm Technologies, INC. | $25.87 | 2024 | Zio Monitor, Zio Xt Patch |
| Medtronic, INC. | $24.59 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $16.10 | 2023 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.66 | 2024 | Lifevest |
| Cardiovascular Systems INC. | $15.60 | 2023 | Diamondback Coronary |
| Merck Sharp & Dohme LLC | $14.65 | 2024 | Bridion |
| Astrazeneca Pharmaceuticals LP | $14.19 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.